DigestRedComo funciona
Red
/
Empresas
Ge
No verificado

Genmab A/S

Sobre qué escribimos

BiotecnologíaFarmacéuticaMedicina - VariosOncologíaSalud

32 Comunicados de prensa

Ver todos los comunicados de prensa
13/06/2026
Cardiología
Tercera edad
Biotecnología
Farmacéutica
Oncología
Salud
Ir de compras
Medicina - Varios
Eventos
Industria
Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
Fuente
Genmab A/S
Editor
Business Wire
1.00
0
21/05/2026
Oncología
Salud
Medicina - Varios
Sanidad
Farmacéutica
Biotecnología
Eventos
Genmab to Highlight Advances Across Its Oncology Portfolio at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress
Fuente
Genmab A/S
Editor
Business Wire
1.00
0
13/04/2026
Industria
Oncología
Salud
Medicina - Varios
Sanidad
Farmacéutica
Biotecnología
Genmab Presents the Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer
Fuente
Genmab A/S
Editor
Business Wire
1.00
0
16/01/2026
Oncología
Higiene alimentaria
Salud
Medicina - Varios
Farmacéutica
Biotecnología
Industria
Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Fuente
Genmab A/S
Editor
Business Wire
1.00
0
07/01/2026
Ciencia
Sanidad
Farmacéutica
Oncología
Técnica
Medicina - Varios
Biotecnología
Tecnología
Salud
Mercado laboral
Industria
Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence
Fuente
Genmab A/S
Editor
Business Wire
1.00
0
29/12/2026
Biotecnología
Sanidad
Salud
Medicina - Varios
Genmab Portfolio Prioritization Update
Fuente
Genmab A/S
Editor
Business Wire
1.00
0
12/12/2025
Mercado de valores
Oncología
Salud
Medicina - Varios
Farmacéutica
Cardiología
Biotecnología
Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period
Fuente
Genmab A/S
Editor
Business Wire
1.00
0
08/12/2025
Eventos
Ferias y Congresos
Industria
Oncología
Salud
Medicina - Varios
Farmacéutica
Cardiología
Biotecnología
Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT)
Fuente
Genmab A/S
Editor
Business Wire
1.00
0
07/12/2025
Industria
Oncología
Salud
Medicina - Varios
Farmacéutica
Cardiología
Biotecnología
Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma
Fuente
Genmab A/S
Editor
Business Wire
1.00
0
06/12/2025
Eventos
Industria
Ciencia
Cardiología
Biotecnología
Farmacéutica
Oncología
Salud
Medicina - Varios
Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)
Fuente
Genmab A/S
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0